In addition to promoting macrophage immunotherapy when used in combination with CD47/SIRPA blockers, BP nanoparticles can also be used to deliver drugs such as siRNA to increase M1 TAMs or inhibit M2 TAMs at tumor sites. This evidence concerns the gene CD47 and neoplasm.